In a germline BRCA2 positive pt with NSCLC after chemoIO frontline and taxotere as a second line, would you consider PARP inhibitors?

This is a challenging situation and one I have encountered in clinic. The data for PARP inhibitors in NSCLC is limited. There have been limited trials for this specific population including NSCLC so I have extrapolated from the breast/ovarian experience.

For instance, there was a phase II clinical of first line veliparib + carbo/taxol in NSCLC - this did not include identification of BRCA mutations - that demonstrated a trend towards benefit (Ramalingan et al, Clin Cancer Res. 2017 Apr 15;23(8)...